Prestige BioPharma프레스티지바이오파마
950210 · KOSPI · ₩950210 · 프레스티지바이오파마
₩5,050▼ ₩10 (0.20%)End-of-day · Oct 27, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | −88.2% | −88.2% | — | — | — | — |
| Operating margin | −470.1% | −470.1% | −9,111.2% | −42,988.4% | — | — |
| Net margin | 155.6% | 155.6% | −4,777.6% | 10,855.9% | — | — |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +1,875.4% | +1,875.4% | +322.4% | — | — | — |
| Operating income growth | −1.9% | −1.9% | +10.5% | −8.0% | −201.0% | — |
| Net income growth | +164.4% | +164.4% | −285.9% | +107.5% | −2,605.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 5.1% | 5.1% | −7.5% | 3.9% | −41.8% | −1.3% |
| Return on assets | 0.6% | 0.6% | −7.7% | −0.5% | −38.2% | −1.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 46.7% | 46.7% | 38.1% | 35.8% | 16.3% | 5.1% |
| Net debt to equity | −4.8% | −4.8% | −25.5% | −8.0% | −62.5% | −79.8% |
| Current ratio | 127.0% | 127.0% | 171.6% | 230.9% | 745.5% | 3,274.4% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Prestige BioPharma / 프레스티지바이오파마 / 950210 / KRX:950210
Source: KRX statistical information